Cytoreductive Nephrectomy After Immunotherapy
Author Information
Author(s): Davis Laura E., Calaway Adam, Singer Eric A., Dason Shawn
Primary Institution: Case Western Reserve University Hospitals Urology Institute, Cleveland, OH, USA
Hypothesis
What is the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma following immunotherapy?
Conclusion
Cytoreductive nephrectomy following immunotherapy is safe and beneficial in appropriately selected patients.
Supporting Evidence
- Patients treated with surgery and interferon had superior outcomes compared to those treated with interferon alone.
- The CARMENA trial showed non-inferiority for treatment with sunitinib alone compared to cytoreductive nephrectomy followed by sunitinib.
- The SURTIME trial found no improvement in progression-free rate between upfront and deferred cytoreductive nephrectomy.
Takeaway
This study looks at how surgery can help patients with kidney cancer that has spread, especially after they have received immunotherapy. It shows that surgery can be a good option for some patients.
Methodology
The review discusses historical and current treatments for metastatic renal cell carcinoma, focusing on cytoreductive nephrectomy and its outcomes in relation to immunotherapy.
Potential Biases
Observational nature of many studies may lead to confounding factors affecting results.
Limitations
The study relies on retrospective data and lacks prospective trials, which may introduce bias.
Participant Demographics
Patients with metastatic renal cell carcinoma, specifics not provided.
Statistical Information
P-Value
p=0.05
Confidence Interval
95% CI 0.36–0.97
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website